Corrections to the Year of Service (YOS) 2021 Polypharmacy: Use of Multiple Central-Nervous System – Active Medications in Older

Relevant to: PDPs, PACE, Cost, MA-PD

This memorandum informs Part D sponsors of corrections to the final YOS 2021 Poly-CNS rates on the 2023 Display Page. As a reminder, starting with the 2021 measurement year, the Pharmacy Quality Alliance (PQA) updated the specifications for the Poly-CNS measure to exclude beneficiaries with a seizure disorder diagnosis during the measurement year. Additionally, the PQA added the serotonin-norepinephrine reuptake inhibitor (SNRIs) and antiepileptics to the Poly-CNS measure medication list.

See the full guidance for more information.